A Simple Method for High-Level Expression of HTLV-1 gp46-I(162-214) Peptide and Its Application for Screening

Shahrzad Behdad,1 Samaneh Dolatabadi,1,* and Jafar Saeidi2

1Department of Microbiology, Faculty of Sciences, Neyshabur Branch, Islamic Azad University, Neyshabur, Khorasan Razavi, IR Iran
2Department of Biology, Faculty of Sciences, Neyshabur Branch, Islamic Azad University, Neyshabur, Khorasan Razavi, IR Iran

*Corresponding author: Dr. Samaneh Dolatabadi, Department of Microbiology, Faculty of Sciences, Neyshabur Branch, Islamic Azad University, Neyshabur, Khorasan Razavi, IR Iran. E-mail: s_dolatabadi1436@yahoo.com

Received 2017 August 23; Revised 2017 October 23; Accepted 2018 February 14.

Abstract

**Background:** Gp46-I(162-214) is a linear peptide derived from human T-lymphotropic virus Type 1 (HTLV-1) gp46-I envelope protein. This protein is commonly used to detect HTLV-1 antibodies during enzyme-linked immunosorbent assay (ELISA) or Western blotting.

**Objectives:** This study reported a simple and efficient method for large-scale preparation of this peptide, which is employed for diagnostic purposes.

**Methods:** This study was a descriptive research. The DNA encoding gp46-I(162-214) was optimized according to *E. coli* codon usage. It was then synthesized and sub cloned into a pGS21a vector. This vector added a His-GST tag to the N-terminus of the protein. The pGS21a-gp46-I(162-214) was transformed into the chemically competent *E. coli* BL21 cells and His-GST-gp46-I(162-214) was expressed as an insoluble form. After the isolation of inclusion bodies, His-GST-gp46-I(162-214) was purified and on-column refolding was performed using Nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography. ELISA was then applied to assess the antigenicity of the His-GST-gp46-I(162-214) protein using sera specimens from HTLV-1 infected patients.

**Results:** The Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) results revealed that His-GST-gp46-I(162-214) protein accounted for 30% of the insoluble proteins. The results of ELISA highlighted concentration-dependent interactions between the refolded His-GST-gp46-I(162-214) and HTLV-1 antibodies. Furthermore, the refolded His-GST-gp46-I(162-214) and synthetic gp46-I(162-214) had similar reactivity.

**Conclusions:** Combination of key strategies including codon optimization, expression as inclusion body, and on-column refolding provide an efficient and facile platform for producing gp46-I(162-214) peptide.

**Keywords:** HTLV-1, Protein Expression, Purification

1. Background

HTLV-1 is a human retrovirus and the etiological agent of multiple disorders [1]. Approximately, 10 to 20 million people are estimated to be infected by HTLV-1 worldwide. These individuals will eventually develop an often rapidly fatal leukemia, a debilitative myelopathy, or they may experience uveitis, infectious dermatitis, or other inflammatory disorders [2].

Screening HTLV-1 carriers is currently the main strategy for disease prevention [1]. Screening is generally performed through ELISA, a highly sensitive and specific method. HTLV-1 infection is confirmed by conducting Western blotting on specimens testing positive in ELISA [1, 3].

Gp46-I (162-214) is a linear peptide with 48 amino acids, which is derived from the conserved region of HTLV-1 gp46 envelope protein, and exhibits specific strong reactivity against HTLV-1 infected sera. It is non-reactive to HTLV-2 positive sera; however, it is used detect anti-HTLV-1 antibodies in ELISA and to differentiate between HTLV-1 and HTLV-2 infections in Western blotting [3-5]. Expression of peptides in *E. coli* is one of the cost-efficient methods for providing diagnostic reagents [6]. However, it is difficult to determine the expression of small peptides in *E. coli* introducing a fusion tag may have a positive effect on peptide expression and purification [7]. Many of small peptides have been successfully expressed in *E. coli* using glutathione S-transferase (GST) tag as a fusion partner [8, 9]. In a previous study, we constructed a recombinant protein derived from both HTLV-I and -II, incorporating linear epitopes of gp46-I, gp46-II, gp21, and p19, which were connected together by a short flexible linker as a spacer arm between epitopes [10]. Generally, purification procedure requires dilution, dialysis steps, and concentration methods. Thus, in the present study, we aimed at proposing a
method to reduce the purification time. We modified and synthesized the gene encoding HTLV-I Gp46-I (162-214) according to *E. coli* codon usage without altering amino acid sequence. The synthetic DNA was subcloned into pGS21a vector and expressed as inclusion body purified and on-column refolded using Ni-NTA affinity chromatography. In addition, we assessed binding capacity of gp46-I(162-214) using ELISA.

**2. Methods**

This study was a descriptive research. All the required reagents were purchased from Sigma Chemical (Missouri, USA). They were of analytical grade unless otherwise indicated. The chimeric protein construction and nucleotide sequencing were performed using Biomatik (Wilmington, USA). Restriction enzymes were purchased from Takara (Kyoto, Japan). Plasmid DNA extraction and gel purification kits were obtained from iNtRON (Daejon, Korea). T4 ligase, DNA marker, and isopropyl β-D-thiogalactopyranoside (IPTG) were purchased from Fermentase (Opelstr, Germany). Protein marker was purchased from SinaClon BioScience Co. (Tehran, Iran) and nickel-charged nitrilotriacetic acid (Ni-NTA) agarose resin from Qiagen (Valencia, USA).

**2.1. Serum Samples**

Serum samples were collected from individuals, who tested positive for HTLV-I (anti-HTLV-I positive) infection. All tests were performed using a commercial immunodiagnostic ELISA kit (HTLV-I/II ELISA 4.0, MP Biomedical, Santa Ana, California, USA). Sampling was conducted in Razavi Hospital, Mashhad, Iran. Control serum samples were also collected from healthy volunteers and tested with ELISA.

**2.2. Construction of Expression Vectors**

To create the expression vector for the gp46-I(162-214), the DNA encoding gp46-I(162-214) was optimized according to *E. coli* codon usage by JAVA codon optimization tool (http://www.jcat.de/). Rare codon analysis tools (https://www.genscript.com/tools/rare-codon-analysis) were used to analyze the codons; they were then synthesized by Biomatik (Wilmington, USA). The synthetic gene was subcloned into the BamHI/EcoRI sites of the pGS21a vector using standard protocols. The gp46-I(162-214) fused with a histidine tag (His-tag) and a GST tag; and enterokinase cleavage site at the N-terminus was expressed from the resulting plasmid, which is referred to as pGS21a-gp46-I(162-214).

**2.3. Fusion Protein Expression**

A single colony harboring pGS21a-gp46-I(162-214) plasmid was inoculated into 15 mL of Luria-Bertani (LB) medium with 100 μg/mL ampicillin and grown overnight at 37°C. The cultures were then diluted 1:100 into 50 mL of LB medium with 100 μg/mL ampicillin. Then the cells were constantly shaken and grown at 37°C until the optical density at 600 nm reached 0.6. Protein expression was then induced with 1 mM IPTG for 4 hours. The expression level was analyzed using SDS/PAGE (4% stacking gel; 12% running gel). The stacking gel ensures that all proteins arrive at the running gel at the same time, and thus, proteins with the same molecular weight will migrate as tight bands [11]. The non-induced controls (as negative controls) were analyzed in parallel with one another.

**2.4. Solubility Testing**

The solubility of His-GST-gp46-I(162-214) was checked for expression under appropriate conditions. The *E. coli* pellets, obtained from 50 mL of culture after IPTG induction, were re-suspended in phosphate-buffered saline (PBS), and samples were subjected to sonication (Bandelin, Germany) on ice. Sonication was performed at a 20 kHz of frequency for 2 minutes, and bacteria were pulsed for 6 × 10 seconds intervals. The cell lysate was then centrifuged at 12,000 rounds per minute (g) and 4°C for 20 minutes. The clear supernatant and pellets were analyzed in 12% polyacrylamide gels using SDS-PAGE.

**2.5. Isolation of Inclusion Bodies**

After being induced by 1 mM IPTG for 4 hours, the cultures were centrifuged at 5000 g for 10 minutes and harvested. One gram of wet weight cells was washed with 0.9% sodium chloride solution and suspended in 3 mL of lysis buffer (containing 50 mM Tris-HCl, 1 mM EDTA, and 100 mM NaCl; pH = 8.0). Lysozyme was added to a concentration of 100 μg/mL and the cells were incubated on ice for 20 minutes. The lysates were treated with ultrasound (power: 200W; on-time and off-time of the ultrasonic pulse: 2 s) at 4°C for 2 minutes. The soluble cell fractions were removed by centrifugation at 12,000 g and 4°C for 10 minutes. The inclusion bodies were washed twice with 2 mL of washing buffer (containing 50 mM Tris-HCl, 100 mM NaCl, and 0.5% Triton X-100; pH = 8.0), collected by centrifugation at 12000 g and 4°C for 10 minutes, and solubilized in 2 mL of buffer (containing 8 M urea, 50 mM Tris-HCl, and 100 mM NaCl; pH = 8.0) at 4°C for 4 hours.

**2.6. Protein Purification**

After being centrifuged at 12,000 g and 4°C for 10 minutes, the proteins were applied to the affinity chromatography column. Following extensive washing with
Behdad S et al.

Binding buffer (containing 20 mM Tris, 500 mM NaCl, and 20 mM imidazole; pH = 8.0), 5 column volumes of elution buffer (containing 20 mM Tris, 500 mM NaCl, and 250 mM imidazole; pH = 8.0) were added to the fusion protein at a flow rate of 1 mL/min. The peak fractions containing the fusion protein were pooled and dialyzed in PBS overnight at 4°C. Bradford protein assay, with bovine serum albumin (BSA) as the standard, were applied to measure protein concentration.

2.7. ELISA

Briefly, 96-well plates were coated with 100 μL of purified protein or synthetic peptide (0 - 25 μg/mL in PBS) and maintained at 4°C overnight. Subsequently, 100 μL of 5% (w/v) nonfat dry milk in PBS was used to block non-specific binding sites. The blocking continued for 1 hour, and then, the plates were washed with PBST (TWEEN 20 in PBS). In the next step, 50 μL of infected serum was added to antigen-coated plates in duplicate wells. After incubation at room temperature for 2 hours, the plates were washed and 100 μL of horseradish peroxidase-conjugated gp46-I(162-214) HTLV-I peptide were added to each well. Incubation was again performed for 1 hour. After washing, the bound antibody was detected using 100 μL of 3,3′,5,5′-tetramethylbenzidine (TMB) solution. Color development was allowed to proceed for 15 minutes and the reaction was stopped with 50 μL of stop solution. Absorbance was determined at 450 nm using an ELISA reader.

3. Results

3.1. Construction of Expression Vector

For subcloning, restriction enzymes BamHI and EcoRI were added to the 5′ end and 3′ end of the gp46-I(162-214) gene, and the gene was optimized according to E. coli codon usage. After optimization, the codon adaptation index (CAI) was improved to 0.88. CAI values above 0.8 indicate that the gene could be overexpressed in E. coli. Moreover, the GC content of the synthetic gene was increased to 55% which was higher than the average GC content of E. coli (i.e., 50%). The optimized sequence was synthesized and subsequently inserted into the pGS21a vector, moreover, and pGS21a-gp46-I(162-214), containing His-GST tag for affinity purification, was obtained. The accuracy of subcloning was verified by DNA sequencing. Following these multiple sequence alignments, we detected a sequence similarity between these peptide amino acid residues and the registered sequences (Figure 1).

Figure 1. Schematic Diagram of the Construct Used for Fusion Expression of gp46-I(162-214)

The gp46-I(162-214) gene was cloned downstream of His-GST tag in pGS21a expression vector.

3.2. Expression of the gp46-I(162-214)

The induced E. coli BL21 (DE3) cell lysate harboring recombinant plasmid was analyzed by SDS-PAGE. The induction time was 4 hours and the IPTG concentration was 1 mM. SDS-PAGE of the lysate of the induced pGS21a-gp46-I(162-214)/BL21 recombinant bacteria revealed a 32-kDa band, corresponding in size to the expected molecular weight of His-GST-gp46-I(162-214) (Figure 1). However, no such band was observed for the non-transformed and non-induced pGS21a/E. coli transformants (Figure 2).

3.3. Solubility Determination

SDS-PAGE of the supernatant and pellet was performed to determine the distribution of the His-GST-gp46-I(162-214) protein in the soluble and insoluble fractions. According to the obtained results, the protein was in the pellet. The results of densitometry and Bradford protein assay revealed that His-GST-gp46-I(162-214) accumulated up to about 30% of the insoluble proteins (Figure 3).

3.4. Purification of His-GST-gp46-I(162-214)

The His-GST-gp46-I(162-214) fusion protein was purified from the solubilized protein aggregates using Ni-NTA affinity chromatography. The proteins without His tags were removed from the Ni-NTA resin using a washing buffer containing 20 mM imidazole. His-tagged His-GST-gp46-I(162-214) was eluted using an elution buffer containing 250 mM imidazole with more than 90% purity (Figure 4).

Zahedan J Res Med Sci. 2018; 20(2):e60736.
3.5. ELISA

ELISA was used to determine the binding activity of the His-GST-gp46-I(162-214) protein to antibodies present in HTLV-I-infected serum. The results revealed that the His-GST-gp46-I(162-214) protein could specifically bind to anti-HTLV-I antibodies. Moreover, comparison of ELISA results for gp46-I(162-214) peptides and refolded His-GST-gp46-I(162-214) indicated that these interactions were highly specific. According to ELISA results, the peptide showed higher optical density absorbance at 450 nm compared to His-GST-gp46-I(162-214). The high immunodominant epitope present on the plate might have been responsible for this finding (Figure 1).

4. Discussion

In this study, we modified and synthesized the gene encoding HTLV-I gp46-I(162-214) to detect anti-HTLV-I antibodies in the serum of suspected patients for screening purposes.

HTLV represents a family of human retroviruses with 4 known members and many subtypes [12]. HTLV-I and HTLV-II are major causes of neurologic disorders and lymphocytic leukemia. Peptides derived from these viruses are the most common and most widely used antigens in the serological tests of HTLV infection worldwide [13]. Syn-
thetic peptides are used to detect HTLV-I/-II antibodies and increase its specificity [14].

Protein expression usually leads to the formation of inclusion bodies at 37°C. The key advantage of expression of proteins as an inclusion body is the high level of expression, which reaches to more than 30% of cellular proteins in some cases [15]. The inclusion bodies can be easily isolated considering their differences in size and density before purification; and this can decrease the number of purification steps. However, the refolding of inclusion bodies to bioactive protein is a highly complicated process [16]. Hence, there has been growing interest in soluble expression of inclusion bodies, which is different from peptide expression. In contrast to full length proteins, peptides do not require time-consuming complete refolding to the 3D structure.

In the present study the DNA encoding of gp46-I(162-214) was codon-optimized according to *E. coli* codon usage because the viral protein sequences contain rare codons for prokaryotic cells. Previous studies reported increased recombinant protein yield following codon optimization [17]. The codon-optimized DNA was subcloned into pG521a which had an additional His-GST tag to the N-terminus of the protein [4]. The addition of His tag allowed protein purification through a one-step strategy. GST tag is a 26 kDa protein and increases peptide size [18]. This can increase the expression level of the peptide because small peptides expressed in *E. coli* cells are usually degraded by different proteases present in the host cell. Fusion of peptides with large-sized tags has been found to increase their expression level. GST tag is highly efficient, when positioned in the N-terminal than in the C-terminal of proteins or peptides [19]. Expression of gp46-I(162-214) was induced with IPTG (final concentration 1 mM) at 37°C for 4 hours. Under such conditions, protein expression led to the formation of inclusion bodies. The obtained cells were harvested and lysed by lysis buffer, and the supernatant was discarded. To remove the residual host proteins and DNA, the inclusion bodies were extensively washed in a buffer containing triton, NaCl, Tween-20, and urea. Ultrasound was also used to remove nucleic acids during the isolation of inclusion bodies. Although the washing step is indispensable, the preliminary work can decrease the difficulties and expenses in the next purification procedures and provide a product of high purity. The isolated inclusion bodies were further purified through immobilized metal affinity chromatography (IMAC) which is a highly selective chromatography method widely used for purification. Here, purity more than 90% was achieved as determined by SDS-PAGE after purification. Such a high purity facilitated the next refolding process. Refolding of insoluble recombinant proteins from inclusion bodies generally involves time-consuming processes such as dialysis or dilution. Because considerable amounts of protein are aggregated and precipitated during these processes, refolding was performed at low concentrations to prevent aggregation [20]. After refolding, the protein solution was first dialyzed to eliminate its urea and detergent content and then concentrated. Histidine tagging of recombinant proteins allows on-column refolding and purification to be performed during one single step [21]. Binding of unfolded proteins occurs because the presence of denaturant does not reduce the affinity of the histidine tag for metal ions. In subsequent washing and elution steps, to allow the one-column refolding of the protein, those buffers should be used that do not contain urea. Immobilization of refolded proteins, on a support can minimize protein aggregation and is thus beneficial. Proper refolding of the protein can be confirmed using a functional assay. Results of 30 HTLV-I-infected serum samples by refolded gp46-I(162-214) and synthetic gp46-I(162-214) showed 100% concordance. The results are in agreement with those reported by Yi-ming et al. who found, that
the c-terminal half of gp46 can detect 97.6% of the positive samples [22]. In another study, E. coli expression system producing p19 protein has been developed by Mosadeghi et al. In their study, codon optimization and GST fusion resulted in high expression and facile purification of the protein. They reported that this p19 fusion protein reacted to HTLV-I antibodies and showed strong sensitivity and specificity and was compatible to the ELISA results of p19 [4], which is similar to our results. In the present study, no cross reactivity was detectable in sera from healthy controls. These data indicated that this experimentally designed antigen showed good specificity.

4.1. Conclusions

In this study, we developed a facile method and presented a strategy for high level expression, purification, and refolding of gp46-I(162-214) to be used in ELISA for screening the suspected cases of HTLV-I infection. Recombinant His-GST-gp46-I(162-214) was purified and refolded using IMAC. Moreover, compared to long and time-consuming purification procedures that require dilution, dialysis, and concentration, the proposed approach reduced the purification and refolding time by integrating all processes in 2 steps. One limitation of this study was that the number of studied HTLV patients was low; and thus, the serodiagnosis might have been under estimated so it should be further investigated in future studies.

Acknowledgments

The authors wish to thank Dr. Hafez Heydari Zarnagh for his excellent support. This study is approved by Islamic Azad University, Nishabur Branch as MS thesis (No. 2343050793201).

Footnotes

Authors’ Contribution: Shahrzad Behdad performed the study as her thesis. Dr. Samaneh Dolatabadi was the Advisor of thesis and manuscript writing, and Dr. Jafar Saeidi acted as material support.

Financial Disclosure: There are not any conflicts of interest.

Funding/Support: This study was financially supported by Islamic Azad University, Neyshabur branch.

References

1. Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23(1):577-89. doi: 10.1128/CMR.00063-09. [PubMed: 20610824].

2. Uchenna Twetewe P, Natukunda B, Bazira J. Human T-Cell Lymphotropic Virus Types 1 and 2 Seropositivity among Blood Donors at Mbarara Regional Blood Bank, South Western Uganda. Leuk Res Treatment. 2016;2016:1675326. doi: 10.1155/2016/1675326. [PubMed: 27034840].

3. Santos RF, Conceicao GC, Martins MS, Kraychete A, Penalva MA, Carvalho EM, et al. Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-I) among maintenance hemodialysis patients. BMC Nephrol. 2017;18(1):64. doi: 10.1186/s12881-017-0484-y. [PubMed: 28202001].

4. Abbasdeghan MR, Jafarzadeh N, Sankian M, Varasteh A, Mahmoudi M, Sadeghizadeh M, et al. Truncated MTA-1: a pitfall in ELISA-based immunoassay of HTLV-I infection. J Biomed Biotechnol. 2008;2008:846371. doi: 10.1155/2008/846371. [PubMed: 18566840].

5. Mosadeghi P, Zarnagh HH, Mohammad-Zadeh M, Salehigohammadi M, High-Level Soluble Expression and One-step Purification of HTLV-I P19 Protein in Escherichia coli by Fusion Expression. Iran J Allergy Asthma Immunol. 2015;14(6):624-32. [PubMed: 26725560].

6. Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv. 2012;30(7):2102-7. doi: 10.1016/j.biotechadv.2011.09.003. [PubMed: 2986845].

7. Liley GG, Dolezal O, Hillyard CJ, Bernard C, Hudson PJ. Recombinant single-chain antibody peptide conjugates expressed in Escherichia coli for the rapid diagnosis of HIV. J Immunol Methods. 1994;179(3):218-26. [PubMed: 7950587].

8. Lichty JJ, Malecki JI, Agnew HD, Michelson-Horowitz DJ, Jan S. Comparison of affinity tags for protein purification. Protein Expr Purif. 2005;41(1):98-105. doi: 10.1016/j.pep.2005.01.019. [PubMed: 15802226].

9. Arnau J, Lauritzen C, Petersen GE, Pedersen J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr Purif. 2006;48(1):31-3. doi: 10.1016/j.pep.2005.12.002. [PubMed: 1642733].

10. Faramarzi R, Dolatabadi S. Expression and purification of recombinant HTLV-III linear epitopes antigen and its application for screening of suspected patients. Iran J Microbiol. 2017;9(1):43-9. [PubMed: 28775823].

11. Hinuma S, Honda S, Tsukamoto K, Sugamura K, Hinuma Y. Production of plasminogen activators by human T-cell leukaemia virus-transformed human T-cell lines. Br J Cancer. 1985;51(6):753-9. [PubMed: 2988592].

12. Karimi G, Zadsar M, Pourfatollah AA. Seroprevalence and geographical distribution of human T-lymphotropic virus type I among volunteer blood donors in endemic areas of Iran. Viral J. 2017;14(1):34. doi: 10.1186/s12985-017-0693-9. [PubMed: 28172724].

13. Zarnagh HH, Ravanshad M, Pourfatollah AA, Raase MJ, Expression and purification of a novel computationally designed antigen for simultaneous detection of htlv-i and hbv antibodies. Iran J Allergy Asthma Immunol. 2015;14(2):268.

14. Davis GD, Elisee C, Newham DM, Harrison RG. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol Bioeng. 1999;65(4):382-8. [PubMed: 1050441].

15. Hwang PM, Pan JS, Sykes BD. Targeted expression, purification, and cleavage of fusion proteins from inclusion bodies in Escherichia coli. FEBS Lett. 2014;588(2):247-52. doi: 10.1016/j.fsl.2013.09.028. [PubMed: 24076468].

16. Yamaguchi H, Miyazaki R. Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies. Biomolecules. 2014;4(1):235-51. doi: 10.3390/biom4010035. [PubMed: 24970214].

17. LI YM, LI DJ, XU XJ, CUI M, ZHEN HH, WANG Q. Effect of codon optimization on expression levels of human cystatin C in Pichia pastoris. Genet Mol Res. 2014;13(3):4990-5000. doi: 10.4238/2014.July.414. [PubMed: 25062487].

Zahedan J Res Med Sci. 2018; 20(2):e60736.
18. Young CL, Britton ZT, Robinson AS. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. *Biotechnol J.* 2012;7(5):620–34. doi: [10.1002/biot.201100155]. [PubMed: 22442034].

19. Mooney JT, Fredericks DP, Christensen T, Bruun Schiodt C, Hearn MT. N-terminal processing of affinity-tagged recombinant proteins purified by IMAC procedures. *J Mol Recognit.* 2015;28(7):401–12. doi: [10.1002/jmr.2456]. [PubMed: 25727088].

20. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. *Annu Rev Biochem.* 2013;82:323–55. doi: [10.1146/annurev-biochem-060208-092442]. [PubMed: 23746257].

21. Xi H, Yuan R, Chen X, Gu T, Cheng Y, Li Z, et al. Purification and on-column refolding of a single-chain antibody fragment against rabies virus glycoprotein expressed in Escherichia coli. *Protein Expr Purif.* 2016;126:26–32. doi: [10.1016/j.pep.2016.05.004]. [PubMed: 27157441].

22. Chen YM, Lee TH, Samuel KP, Okayama A, Tachibana N, Miyoshi I, et al. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people. *J Virol.* 1989;63(11):4952-7. [PubMed: 2677406].